Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Zeitschrift für Rheumatologie
Erschienen in: Zeitschrift für Rheumatologie 2/2016

01.08.2016 | Arthritis | Leitlinie

Langfassung zur S2e-Leitlinie Gichtarthritis (fachärztlich)

Evidenzbasierte Leitlinie der Deutschen Gesellschaft für Rheumatologie (DGRh)

verfasst von: Dr. med. U. Kiltz, Dr. med. R. Alten, Prof. Dr. med. M. Fleck, Prof. Dr. K. Krüger, Prof. Dr. med. B. Manger, Prof. Dr. med. U. Müller-Ladner, Prof. Dr. med. H. Nüßlein, Prof. Dr. med. M. Reuss-Borst, Prof. Dr. med. A. Schwarting, Prof. Dr. med. H. Schulze-Koops, Dr. med. A. Tausche, Prof. Dr. med. J. Braun

Erschienen in: Zeitschrift für Rheumatologie | Sonderheft 2/2016

Einloggen, um Zugang zu erhalten

Auszug

Convenor: Prof. Dr. J. Braun …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
3.
4.
Kuo CF et al (2014) Rising burden of gout in the UK but continuing suboptimal management: A nationwide population study. Ann Rheum Dis 74(4):661–667PubMedPubMedCentralCrossRef
5.
6.
Kuo CF et al (2015) Global epidemiology of gout: Prevalence, incidence and risk factors. Nat Rev Rheumatol 11(11):649–662PubMedCrossRef
7.
8.
Wallace KL et al (2004) Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 31(8):1582–1587PubMed
9.
Annemans L et al (2008) Gout in the UK and Germany: Prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 67(7):960–966PubMedCrossRef
10.
Jing J et al (2014) Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: The German Chronic Kidney Disease (GCKD) study. Nephrol Dial Transplant. doi:10.​1093/​ndt/​gfu352 PubMed
11.
Zhu Y, Pandya BJ, Choi HK (2012) Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med 125(7):679–687.e1PubMedCrossRef
12.
Campion EW, Glynn RJ, DeLabry LO (1987) Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 82(3):421–426PubMedCrossRef
13.
14.
Bomalaski JS, Lluberas G, Schumacher HR Jr. (1986) Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout. Arthritis Rheum 29(12):1480–1484PubMedCrossRef
15.
Dalbeth N, Stamp L (2014) Hyperuricaemia and gout: Time for a new staging system? Ann Rheum Dis 73(9):1598–1600PubMedCrossRef
16.
Gutman AB (1973) The past four decades of progress in the knowledge of gout, with an assessment of the present status. Arthritis Rheum 16(4):431–445PubMedCrossRef
17.
Khanna PP et al (2012) Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health Qual Life Outcomes 10:117PubMedPubMedCentralCrossRef
18.
Scire CA et al (2013) Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: Results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther 15(5):R101PubMedPubMedCentralCrossRef
19.
20.
Sarawate CA et al (2006) Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 12(2):61–65PubMedCrossRef
21.
Shields GE, Beard SM (2015) A systematic review of the economic and humanistic burden of gout. Pharmacoeconomics 33(10):1029–1047PubMedCrossRef
22.
Pascual E, Sivera F, Andres M (2011) Synovial fluid analysis for crystals. Curr Opin Rheumatol 23(2):161–169PubMed
23.
Khanna D et al (2012) American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64(10):1431–1446CrossRef
24.
25.
Zhang W et al (2006) EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65(10):1301–1311PubMedPubMedCentralCrossRef
26.
Schlesinger N, Norquist JM, Watson DJ (2009) Serum urate during acute gout. J Rheumatol 36(6):1287–1289PubMedCrossRef
27.
Janssens HJ et al (2010) A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med 170(13):1120–1126PubMedCrossRef
28.
Kienhorst LB et al (2015) The validation of a diagnostic rule for gout without joint fluid analysis: A prospective study. Rheumatology (Oxford) 54(4):609–614CrossRef
29.
Dalbeth N et al (2007) Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology (Oxford) 46(12):1804–1807CrossRef
30.
Ogdie A et al (2015) Imaging modalities for the classification of gout: Systematic literature review and meta-analysis. Ann Rheum Dis 74(10):1868–1874PubMedCrossRef
31.
Chowalloor PV, Keen HI (2013) A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia. Ann Rheum Dis 72(5):638–645PubMedCrossRef
32.
Ottaviani S et al (2012) Ultrasonography in gout: A case-control study. Clin Exp Rheumatol 30(4):499–504PubMed
33.
Naredo E et al (2014) Ultrasound-detected musculoskeletal urate crystal deposition: Which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis 73(8):1522–1528PubMedCrossRef
34.
Choi HK et al (2012) Dual energy CT in gout: A prospective validation study. Ann Rheum Dis 71(9):1466–1471PubMedCrossRef
35.
Huppertz A et al (2014) Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout. Rheumatol Int 34(6):763–771PubMedCrossRef
36.
Bongartz T et al (2015) Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis 74(6):1072–1077PubMedCrossRef
37.
Melzer R et al (2014) Gout tophus detection – a comparison of dual-energy CT (DECT) and histology. Semin Arthritis Rheum 43(5):662–665PubMedCrossRef
38.
Khanna D et al (2012) American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64(10):1447–1461CrossRef
39.
Sriranganathan MK et al (2014) Interventions for tophi in gout: A Cochrane systematic literature review. J Rheumatol Suppl 92:63–69PubMedCrossRef
40.
Khanna PP et al (2014) Treatment of acute gout: A systematic review. Semin Arthritis Rheum 44(1):31–38PubMedCrossRef
41.
van Durme CM et al (2014) Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev 9:CD010120PubMed
42.
Rees F, Hui M, Doherty M (2014) Optimizing current treatment of gout. Nat Rev Rheumatol 10(5):271–283PubMedCrossRef
43.
Altman RD et al (1988) Ketoprofen versus indomethacin in patients with acute gouty arthritis: A multicenter, double blind comparative study. J Rheumatol 15(9):1422–1426PubMed
44.
45.
Maccagno A, Di Giorgio E, Romanowicz A (1991) Effectiveness of etodolac (‘Lodine’) compared with naproxen in patients with acute gout. Curr Med Res Opin 12(7):423–429PubMedCrossRef
46.
Rubin BR et al (2004) Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial. Arthritis Rheum 50(2):598–606PubMedCrossRef
47.
Reardon JA et al (1980) Double-blind trial of feprazone and phenylbutazone in acute gout. Curr Med Res Opin 6(7):445–448PubMedCrossRef
48.
Janssens HJ et al (2008) Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial. Lancet 371(9627):1854–1860PubMedCrossRef
49.
Li T et al (2013) Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: A randomized double-blind trial. Chin Med J (Engl) 126(10):1867–1871
50.
Schumacher HR et al (2012) Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: A randomized controlled trial. J Rheumatol 39(9):1859–1866PubMedCrossRef
51.
52.
Terkeltaub RA et al (2010) High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62(4):1060–1068PubMedCrossRef
53.
van Echteld I et al (2014) Colchicine for acute gout. Cochrane Database Syst Rev 8:CD006190PubMed
54.
Schlesinger N et al (2002) Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 29(2):331–334PubMed
55.
Ahern MJ et al (1987) Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 17(3):301–304PubMedCrossRef
56.
Janssens HJ et al (2008) Systemic corticosteroids for acute gout. Cochrane Database Syst Rev 2:CD005521PubMed
57.
Wechalekar MD et al (2013) Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev 4:CD009920PubMed
58.
Fernandez C et al (1999) Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 26(10):2285–2286PubMed
59.
Komatsu T (1969) Treatment of acute gouty attack with local infiltration of Kenacort – A and the study of gout and hyperuricemia at the Tanabe National Hospital during 1967. Iryo 23(1):54–61PubMed
60.
Schlesinger N et al (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: Results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71(11):1839–1848PubMedCrossRef
61.
Schlesinger N et al (2011) Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: Results of a randomized, dose-ranging study. Arthritis Res Ther 13(2):R53PubMedPubMedCentralCrossRef
62.
So A et al (2010) Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 62(10):3064–3076PubMedCrossRef
63.
Schlesinger N et al (2011) Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: Results of a double-blind, randomised study. Ann Rheum Dis 70(7):1264–1271PubMedPubMedCentralCrossRef
64.
Mitha E et al (2013) Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: Results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford) 52(7):1285–1292CrossRef
65.
Schumacher HR Jr. et al (2012) Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 64(3):876–884PubMedCrossRef
66.
Terkeltaub RA et al (2013) Rilonacept in the treatment of acute gouty arthritis: A randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 15(1):R25PubMedPubMedCentralCrossRef
67.
Schumacher HR Jr. et al (2012) Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) 64(10):1462–1470CrossRef
68.
69.
Thueringer JT, Doll NK, Gertner E (2015) Anakinra for the treatment of acute severe gout in critically ill patients. Semin Arthritis Rheum 45(1):81–85PubMedCrossRef
70.
Tran AP, Edelman J (2011) Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis 14(3):e33–7PubMedCrossRef
71.
Richette P et al (2014) Updated Eular evidence-based recommendations for gout. Part II: management. Ann Rheum Dis 2014;73(Suppl2):783
72.
Taylor TH et al (2012) Initiation of allopurinol at first medical contact for acute attacks of gout: A randomized clinical trial. Am J Med 125(11):1126–1134.e7PubMedCrossRef
73.
Shoji A, Yamanaka H, Kamatani N (2004) A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51(3):321–325PubMedCrossRef
74.
Pascual E, Sivera F (2007) Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 66(8):1056–1058PubMedPubMedCentralCrossRef
75.
Perez-Ruiz F et al (2002) Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 47(4):356–360PubMedCrossRef
76.
Andres M et al (2014) Treatment target and followup measures for patients with gout: A systematic literature review. J Rheumatol Suppl 92:55–62PubMedCrossRef
77.
Rees F, Jenkins W, Doherty M (2013) Patients with gout adhere to curative treatment if informed appropriately: Proof-of-concept observational study. Ann Rheum Dis 72(6):826–830PubMedCrossRef
78.
Kuo CF et al (2014) Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA 312(24):2684–2686PubMedCrossRef
79.
Briesacher BA et al (2008) Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28(4):437–443PubMedPubMedCentralCrossRef
80.
81.
Perez-Ruiz F, Herrero-Beites AM, Carmona L (2011) A two-stage approach to the treatment of hyperuricemia in gout: The “dirty dish” hypothesis. Arthritis Rheum 63(12):4002–4006PubMedCrossRef
82.
Tausche AK et al (2014) As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatol Int 34(1):101–109PubMedCrossRef
83.
Seth R et al (2014) Allopurinol for chronic gout. Cochrane Database Syst Rev 10:CD006077PubMed
84.
Stamp LK et al (2012) Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. Arthritis Rheum 64(8):2529–2536PubMedCrossRef
85.
Stamp LK et al (2014) Impaired response or insufficient dosage? Examining the potential causes of “inadequate response” to allopurinol in the treatment of gout. Semin Arthritis Rheum 44(2):170–174PubMedPubMedCentralCrossRef
86.
Stamp LK et al (2011) Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 63(2):412–421PubMedCrossRef
87.
Ramasamy SN et al (2013) Allopurinol hypersensitivity: A systematic review of all published cases, 1950–2012. Drug Saf 36(10):953–980PubMedCrossRef
88.
Kim SC et al (2013) Severe cutaneous reactions requiring hospitalization in allopurinol initiators: A population-based cohort study. Arthritis Care Res (Hoboken) 65(4):578–584CrossRef
89.
Halevy S et al (2008) Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 58(1):25–32PubMedCrossRef
90.
Hershfield MS et al (2013) Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 93(2):153–158PubMedCrossRef
91.
Becker MA et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450–2461PubMedCrossRef
92.
Schumacher HR Jr. et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59(11):1540–1548PubMedCrossRef
93.
Becker MA et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial. Arthritis Res Ther 12(2):R63PubMedPubMedCentralCrossRef
94.
95.
Chohan S (2011) Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol 38(9):1957–1959PubMedCrossRef
96.
Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME (2012) Febuxostat for treating chronic gout. Cochrane Database Syst Rev 11:CD008653PubMedPubMedCentral
97.
Ye P et al (2013) Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: A systematic review and meta-analysis. Clin Ther 35(2):180–189PubMedCrossRef
98.
Grewal HK, Martinez JR, Espinoza LR (2014) Febuxostat: drug review and update. Expert Opin Drug Metab Toxicol 10(5):747–758PubMedCrossRef
99.
Jansen TL et al (2010) International position paper on febuxostat. Clin Rheumatol 29(8):835–840PubMedCrossRef
100.
Faruque LI et al (2013) A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum 43(3):367–375PubMedCrossRef
101.
102.
Reinders MK et al (2009) A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis 68(6):892–897PubMedCrossRef
103.
Kydd AS et al (2014) Uricosuric medications for chronic gout. Cochrane Database Syst Rev 11:CD010457PubMed
104.
Okuda C et al (2011) Serum CRP in patients with gout and effects of benzbromarone. Int J Clin Pharmacol Ther 49(3):191–197PubMedCrossRef
105.
Johnson RJ et al (2005) Uric acid, evolution and primitive cultures. Semin Nephrol 25(1):3–8PubMedCrossRef
106.
Anderson A, Singh JA (2010) Pegloticase for chronic gout. Cochrane Database Syst Rev 3:CD008335PubMed
107.
Strand V et al (2012) Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: Evidence from phase III randomized controlled trials. J Rheumatol 39(7):1450–1457PubMedCrossRef
108.
Sundy JS et al (2011) Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials. JAMA 306(7):711–720PubMedCrossRef
109.
Lee YH, Lee CH, Lee J (2006) Effect of fenofibrate in combination with urate lowering agents in patients with gout. Korean J Intern Med 21(2):89–93PubMedPubMedCentralCrossRef
110.
Saar J, Kirch W (2014) A new application for well-known pharmaceutics – losartan and fenofibrate as potential remedies against gout? Dtsch Med Wochenschr 139(12):608PubMedCrossRef
111.
Hosoya T et al (2012) Effects of combined antihypertensive therapy with losartan/hydrochlorothiazide on uric acid metabolism. Intern Med 51(18):2509–2514PubMedCrossRef
112.
Miao Y et al (2011) Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 58(1):2–7PubMedCrossRef
113.
McGill NW (2000) Gout and other crystal-associated arthropathies. Baillieres Best Pract Res Clin Rheumatol 14(3):445–460PubMedCrossRef
114.
Rothenbacher D et al (2011) Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford) 50(5):973–981CrossRef
115.
Wortmann RL et al (2010) Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 32(14):2386–2397PubMedCrossRef
116.
Dalbeth N et al (2014) Zoledronate for prevention of bone erosion in tophaceous gout: A randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 73(6):1044–1051PubMedCrossRef
117.
Becker MA et al (2009) Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 36(6):1273–1282PubMedCrossRef
118.
Kramer HM, Curhan G (2002) The association between gout and nephrolithiasis: The National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis 40(1):37–42PubMedCrossRef
119.
120.
Krishnan E (2013) Chronic kidney disease and the risk of incident gout among middle-aged men: A seven-year prospective observational study. Arthritis Rheum 65(12):3271–3278PubMedCrossRef
121.
Jalal DI et al (2013) Uric acid as a target of therapy in CKD. Am J Kidney Dis 61(1):134–146PubMedCrossRef
122.
Liu WC et al (2012) Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 7(4):541–548PubMedCrossRef
123.
Chang HY et al (2010) Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci 339(6):509–515PubMedCrossRef
124.
125.
Whelton A et al (2011) Renal function in gout: Long-term treatment effects of febuxostat. J Clin Rheumatol 17(1):7–13PubMedCrossRef
126.
Sedaghat S et al (2013) Serum uric acid and chronic kidney disease: The role of hypertension. PLoS ONE 8(e76827):11
127.
Chang HY et al (2013) Hyperuricemia is an independent risk factor for new onset micro-albuminuria in a middle-aged and elderly population: A prospective cohort study in taiwan. PLoS ONE 8(4):e61450PubMedPubMedCentralCrossRef
128.
Levy GD et al (2014) Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. J Rheumatol 41(5):955–962PubMedCrossRef
129.
Siu YP et al (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47(1):51–59PubMedCrossRef
130.
Goicoechea M et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5(8):1388–1393PubMedPubMedCentralCrossRef
131.
Sircar D et al (2015) Efficacy of Febuxostat for slowing the GFR decline in patients with CKD and asymptomatic Hyperuricemia: A 6‑month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. doi:10.​1053/​j.​ajkd.​2015.​05.​017 PubMed
132.
Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. JAMA 300(8):924–932PubMedPubMedCentralCrossRef
133.
Zhang W et al (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65(10):1312–1324PubMedPubMedCentralCrossRef
134.
Choi HK et al (2004) Alcohol intake and risk of incident gout in men: A prospective study. Lancet 363(9417):1277–1281PubMedCrossRef
135.
Dalbeth N, Gow P (2006) Alcohol excess may be overemphasised in gout treated in secondary care. N Z Med J 119(1243):U2270PubMed
136.
Choi JW et al (2008) Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: The Third National Health and Nutrition Examination Survey. Arthritis Rheum 59(1):109–116PubMedCrossRef
137.
Choi HK et al (2005) Obesity, weight change, hypertension, diuretic use, and risk of gout in men: The health professionals follow-up study. Arch Intern Med 165(7):742–748PubMedCrossRef
138.
Singh JA, Reddy SG, Kundukulam J (2011) Risk factors for gout and prevention: A systematic review of the literature. Curr Opin Rheumatol 23(2):192–202PubMedPubMedCentral
139.
Wang M et al (2013) A meta-analysis of alcohol consumption and the risk of gout. Clin Rheumatol 32(11):1641–1648PubMedCrossRef
140.
Andres M et al (2014) Dietary supplements for chronic gout. Cochrane Database Syst Rev 10:CD010156PubMed
141.
Moi JH et al (2013) Lifestyle interventions for chronic gout. Cochrane Database Syst Rev 5:CD010039PubMed
142.
Stamp LK et al (2013) Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: A pilot randomized controlled trial. Arthritis Rheum 65(6):1636–1642PubMedCrossRef
143.
Dalbeth N et al (2012) Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: A proof-of-concept randomised controlled trial. Ann Rheum Dis 71(6):929–934PubMedCrossRef
144.
Wang W, Krishnan E (2015) Cigarette smoking is associated with a reduction in the risk of incident gout: results from the Framingham Heart Study original cohort. Rheumatology (Oxford) 54(1):91–95CrossRef
145.
Choi HK, Curhan G (2007) Independent impact of gout on mortality and risk for coronary heart disease. Circulation 116(8):894–900PubMedCrossRef
146.
Riedel AA et al (2004) Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 10(6):308–314PubMedCrossRef
147.
148.
149.
Kuo CF et al (2012) Increased risk of cancer among gout patients: A nationwide population study. Joint Bone Spine 79(4):375–378PubMedCrossRef
150.
Savarese G et al (2013) Changes in serum uric acid levels and cardiovascular events: A meta-analysis. Nutr Metab Cardiovasc Dis 23(8):707–714PubMedCrossRef
151.
Lottmann K, Chen X, Schadlich PK (2012) Association between gout and all-cause as well as cardiovascular mortality: A systematic review. Curr Rheumatol Rep 14(2):195–203PubMedPubMedCentralCrossRef
152.
Dutta A et al (2013) Uric acid measurement improves prediction of cardiovascular mortality in later life. J Am Geriatr Soc 61(3):319–326PubMedCrossRef
153.
Stack AG et al (2013) Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 106(7):647–658PubMedCrossRef
154.
Kuo CF et al (2010) Gout: An independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 49(1):141–146CrossRef
155.
Teng GG et al (2012) Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis 71(6):924–928PubMedCrossRef
156.
Krishnan E et al (2011) Hyperuricemia and the risk for subclinical coronary atherosclerosis – data from a prospective observational cohort study. Arthritis Res Ther 13(2):R66PubMedPubMedCentralCrossRef
157.
Kim SY et al (2010) Hyperuricemia and coronary heart disease: A systematic review and meta-analysis. Arthritis Care Res (Hoboken) 62(2):170–180
158.
Trkulja V, Car S (2012) On-admission serum uric acid predicts outcomes after acute myocardial infarction: Systematic review and meta-analysis of prognostic studies. Croat Med J 53(2):162–172PubMedPubMedCentralCrossRef
159.
De Vera MA et al (2010) Independent impact of gout on the risk of acute myocardial infarction among elderly women: A population-based study. Ann Rheum Dis 69(6):1162–1164PubMedPubMedCentralCrossRef
160.
Li M et al (2014) Hyperuricemia and risk of stroke: A systematic review and meta-analysis of prospective studies. Atherosclerosis 232(2):265–270PubMedCrossRef
161.
Nyrnes A et al (2014) Uric acid is associated with future atrial fibrillation: An 11-year follow-up of 6308 men and women – the Tromso Study. Europace 16(3):320–326PubMedCrossRef
162.
Grayson PC et al (2011) Hyperuricemia and incident hypertension: A systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63(1):102–110CrossRef
163.
Huang H et al (2014) Uric acid and risk of heart failure: A systematic review and meta-analysis. Eur J Heart Fail 16(1):15–24PubMedCrossRef
164.
Tamariz L et al (2011) Uric acid as a predictor of all-cause mortality in heart failure: A meta-analysis. Congest Heart Fail 17(1):25–30PubMedCrossRef
165.
Wu AH et al (2010) Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. Am Heart J 160(5):928–933PubMedCrossRef
166.
167.
Hamaguchi S et al (2011) Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol 151(2):143–147PubMedCrossRef
168.
Hueskes BA et al (2012) A case–control study of determinants for the occurrence of gouty arthritis in heart failure patients. Eur J Heart Fail 14(8):916–921PubMedCrossRef
169.
Jia Z et al (2013) Serum uric acid levels and incidence of impaired fasting glucose and type 2 diabetes mellitus: A meta-analysis of cohort studies. Diabetes Res Clin Pract 101(1):88–96PubMedCrossRef
170.
Xu Y et al (2013) Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: A meta-analysis. PLoS ONE 8(10):e78206PubMedPubMedCentralCrossRef
171.
Lv Q et al (2013) High serum uric acid and increased risk of type 2 diabetes: A systemic review and meta-analysis of prospective cohort studies. PLoS ONE 8(2):e56864PubMedPubMedCentralCrossRef
172.
173.
Rodriguez G, Soriano LC, Choi HK (2010) Impact of diabetes against the future risk of developing gout. Ann Rheum Dis 69(12):2090–2094PubMedCrossRef
174.
Chen JH et al (2013) Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study. Arthritis Care Res (Hoboken) 65(1):133–140CrossRef
175.
Hueskes BA et al (2012) Use of diuretics and the risk of gouty arthritis: A systematic review. Semin Arthritis Rheum 41(6):879–889PubMedCrossRef
176.
McAdams-DeMarco MA et al (2012) Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: The Atherosclerosis Risk in Communities cohort study. Arthritis Rheum 64(1):121–129PubMedPubMedCentralCrossRef
177.
Zhang Y et al (2014) Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis 73(2):385–390PubMedCrossRef
178.
Spencer K, Carr A, Doherty M (2012) Patient and provider barriers to effective management of gout in general practice: A qualitative study. Ann Rheum Dis 71(9):1490–1495PubMedCrossRef
179.
Solomon DH et al (2008) Uric acid lowering therapy: Prescribing patterns in a large cohort of older adults. Ann Rheum Dis 67(5):609–613PubMedCrossRef
180.
181.
Rashid N et al (2015) Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol 42(3):504–512PubMedCrossRef
182.
Sarawate CA et al (2006) Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 81(7):925–934PubMedCrossRef
183.
Dalbeth N et al (2012) Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. Bmc Musculoskelet Disord 13:174PubMedPubMedCentralCrossRef
184.
Roddy E et al (2010) Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford) 49(1):105–111CrossRef
185.
Kuo CF et al (2013) Risk of myocardial infarction among patients with gout: A nationwide population-based study. Rheumatology (Oxford) 52(1):111–117CrossRef
186.
Neogi T et al (2015) Ann Rheum Dis / Arthritis Rheumatol 67(10):2557–2568CrossRef
Metadaten
Titel
Langfassung zur S2e-Leitlinie Gichtarthritis (fachärztlich)
Evidenzbasierte Leitlinie der Deutschen Gesellschaft für Rheumatologie (DGRh)
verfasst von
Dr. med. U. Kiltz
Dr. med. R. Alten
Prof. Dr. med. M. Fleck
Prof. Dr. K. Krüger
Prof. Dr. med. B. Manger
Prof. Dr. med. U. Müller-Ladner
Prof. Dr. med. H. Nüßlein
Prof. Dr. med. M. Reuss-Borst
Prof. Dr. med. A. Schwarting
Prof. Dr. med. H. Schulze-Koops
Dr. med. A. Tausche
Prof. Dr. med. J. Braun
Publikationsdatum
01.08.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe Sonderheft 2/2016
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-016-0147-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise